Lipids and Cardiovascular Diseases: A Translational Outlook from Basic Molecular Mechanisms to Clinical Management

ONLINEWEBINARDHPACCME

Add to Calendar Lipids and Cardiovascular Diseases: A Translational Outlook from Basic Molecular Mechanisms to Clinical Management 9/22/2021 3:00:00 PM 9/22/2021 6:30:00 PM Asia/Riyadh For More Details: https://wcmq.cloud-cme.com/course/courseoverview?EID=1984 Description: Lipid disorders are highly prevalent in Qatar. In this activity, the learner will understand about the basic science related to lipid disorders along with the clinical diagnosis of lipid disorders and recent advancements in therapy as well as the updated guideline recommendations.Registration open for PHYSICIANS ONLY. Online via Zoom false MM/DD/YYYY


Date & Location
Wednesday, September 22, 2021, 3:00 PM - 6:30 PM

Overview

Lipid disorders are highly prevalent in Qatar. In this activity, the learner will understand about the basic science related to lipid disorders along with the clinical diagnosis of lipid disorders and recent advancements in therapy as well as the updated guideline recommendations.

Registration open for PHYSICIANS ONLY.


Target Audience
Specialties - Physicians

Overall Learning Objective
  1. 1- Identify the basics of lipid cholesterol and metabolism
  2. 2- Recognize the different types of lipid disorders
  3. 3- Interpret the methods for lipid level measurement and estimation
  4. 4- Recognize the updated American guidelines for management of lipid disorders

Registration

For PHYSICIANS ONLY.

In recognition of the challenges of the Covid pandemic, the division of CPD of WCM-Q would like to support the Continuing Professional Development of our Health Care Practitioner community by waiving the fees for this event.

The registration closes ONE day before the activity. You will receive a UNIQUE join link on the day of the presentation.


Accreditation

Weill Cornell Medicine-Qatar is accredited as a provider of Continuing Medical Education (CME) and Continuing Professional Development (CPD) by the Department of Healthcare Professions (DHP) of the Ministry of Public Health.

 

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Ministry of Public Health's Department of Healthcare Professions-Accreditation Section and is approved for a maximum of 3 hours. 

 

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

 

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Disclosure of Relationships/Content Validity

It is the policy of Weill Cornell Medicine-Qatar to adhere to Ministry of Public Health's Department of Healthcare Professions (DHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias. 

 

Course Director: Nasrin Mesaeli, PhD, has no relevant financial relationship to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

 

Course Faculty: Tariq Chukir, MD, Moncef Ladjimi, PhD, Nasrin Mesaeli, PhD, Hani Najafi, PhD, Ahmed Soliman, MD, have no relevant financial relationship to disclose and will not be discussing unlabeled/unapproved use of drugs or products.

 

Course Faculty: Mohamed Elshazly, MD, has disclosed the following: Ownership Interest – Ember Medical; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

 Seth Martin, MD, has disclosed the following: Grants/Research Support Recipient – Amgen; Advisor or Review Panel Member – Amgen, Sanofi-Aventis, AstraZeneca, DalCor, 89bio; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products. 

 Erin Michos, MD, has disclosed the following: Advisor or Review Panel Member – AstraZeneca, Novartis AG, Bayer Corporation, Novo Nordisk, Esperion, Amarin; WILL be discussing statins, inclisiran, bempedoic acid, icosapent ethyl; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products. 


 

Course Director and Faculty: Islam Elgendy, MD, has disclosed the following: Grants/Research Support Recipient and Consulting fee – Caladrius Biosciences; The financial relationship is not relevant; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products. 

 

Administrative Contact: Safia Rabia has disclosed the following: Spouse, employee – Al-Wehda Medical Group; The financial relationship is not relevant; WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

 

ICR: Nasrin Mesaeli, PhD, has no relevant financial relationship to disclose and WILL NOT BE DISCUSSING any unlabeled/unapproved use of drugs or products.

 

The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.